Cyxone announces promising preclinical results supporting T20K combination therapy for multiple sclerosis
Cyxone (publ) announces today that the company, together with its academic partner Medical University of Vienna, has continued to investigate the drug candidate T20K in combination with a kappa opioid receptor agonist. A combination which in pre-clinical experiments demonstrate promising synergistic therapeutic effects and potential disease modifying features in multiple sclerosis. The results build upon previous data which underpin a patent application to the European Patent Office that recently was made public.Multiple sclerosis (MS) is a chronic autoimmune disease that emerges when the